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Objective. To investigate the incidence of various antiphospholipid antibodies (aPLs), measured by commercial-based laboratory,
with recurrent spontaneous abortion (RSA) patients and the impact of the species, isotype, titer, and number of positive aPLs on
reproductive outcome in Japanese. Method. In this retrospective cohort study, 263 patients with RSA without possible causes were
investigated. Of 131 patients with one or more positive aPL, 82 pregnant women under anticoagulant therapy were evaluated.
Results. The incidence of various aPLs was almost consistent with previous report. Overall, successful pregnancy rate with
anticoagulant therapy was 91.4% regardless of aPL proﬁles. There was no signiﬁcant diﬀerence in the pregnancy maintenance
rate between IgG and IgM groups or single positive and multiple positive groups, but there was a tendency for the rate with aspirin
to be lower than with aspirin plus heparin in IgG group. Conclusion. aPL proﬁle did not aﬀect the pregnancy maintenance rate
when anticoagulant therapy was actively introduced, however in IgG group, we recommend combination therapy with aspirin and
heparin.
1.Introduction
Since the pathogenic association of antiphospholipid anti-
body (aPL) with recurrent spontaneous abortions (RSA) was
reported, the eﬃcacy of anticoagulant therapy for patients
that have undergone RSA and have positive aPL has been
investigated [1–4]. Regarding test items of aPLs for RSA,
an international consensus statement concerning the update
of the classiﬁcation criteria for deﬁnite antiphospholipid
syndrome (APS), published in February 2006 [5], speciﬁed
only anticardiolipin antibody (aCL) of IgG and/or IgM
isotype in a medium or high titer (over the 99th percentile),
anticardiolipin-β2 glycoprotein-I antibody (aβ2GPI) of IgG
and/or IgM isotype (over the 99th percentile), and lupus
anticoagulant (LA). For these patients met with above
laboratory criteria and clinical criteria for APS, a treatment
combining oral aspirin with the subcutaneous injection of
unfractionated heparin has been regarded as superior to
aspirin alone [6, 7]. However, various other aPLs, such
as antiphosphatidylserine antibody (aPS) [8], antiphos-
phatidylethanolamine antibody (aPE) [9, 10], and others
[11] have been considered to be involved in the etiology
of RSA, but these aPLs are not mentioned in these revised
classiﬁcation criteria. Moreover, the relevance of isotypes,
titer, or the number of positive aPLs in RSA has not been
clariﬁed. In fact, we see many RSA patients, not met the
criteria for APS, but had one or more positive aPL. In the
meantime,asforthedetectionofaPLs,laboratorycriteriaare
not always reproducible because of well-known inter- and/or
intralaboratory variability [12]. In Japan, a few facilities are
testing aPLs in their own laboratory and in many other
facilities,aPLsaremeasuredbycommercial-basedlaboratory
reporting the 95th percentile and more as positive result,
so the interpretation of the result needs to be careful.2 ISRN Obstetrics and Gynecology
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Parentheses: case number, RSA: recurrent spontaneous abortion, aPLs: antiphospholipid antibodies.
RSA (327)
With possible causes (64)
Without possible causes (263)
Negative aPLs (132)
Positive aPLs (131)
Conceived (82)
Maintained pregnancy (74)
Aborted (8)
Normal karyotype (7)
Aberrant karyotype (1)
Not conceived (49)
Figure 1: Patients groups and numbers investigated for the incidence of aPLs and reproductive outcomes of the anticoagulant therapy.
On the other hand, almost all RSA patients with one or more
positive aPL (the 95th percentile and more) prefer actively
to be introduced an anticoagulant therapy for their next
pregnancy.
Given the above background, we examined aPE and aPS
of IgG and IgM antibodies in addition to LA, aβ2GPI, and
aCL described in the classiﬁcation criteria for deﬁnite APS
and investigated the impact of antibody titers by classifying
them into weakly (from the 95th to the 99th percentile)
and strongly (over the 99th percentile), antibody isotypes
of IgG and IgM, and the numbers of positive antibodies of
single and multiple on reproductive outcome. We designed
this retrospective cohort study, and our study focused on
the incidence of various aPLs with RSA patients, measured
by commercial-based laboratory and the impact of their
proﬁles on reproductive outcomes with active anticoagulant
therapy in order to develop individualization of treatment
for patients with RSA, because the subcutaneous injection of
heparin requires daily self-injection during the entire period
of pregnancy, so this treatment is very stressful for patients.
2.MaterialsandMethods
2.1. Study Design. This retrospective cohort study was
designed to evaluate the incidence of various aPLs, mea-
sured by commercial-based laboratory, in patients that had
undergone RSA and to determine whether aPL proﬁles aﬀect
reproductive outcomes with the anticoagulant therapy in
order to develop individualization of treatment in these
patients. The Jikei University Institutional Review Board
approved the study design.
2.2. Patients. Records were evaluated for 327 patients that
had undergone RSA who visited the outpatient infertility
clinic in Jikei University Hospital between November 2005
and July 2009. These patients had suﬀered 2 or more
consecutive spontaneous abortions before the 12th week of
gestation (= RSA patients) and were examined by routine
checkup for RSA. Then, 64 patients were positive for
routine checkup that included anatomical, endocrine, or
chromosomal aberration, complications of SLE, or other
autoimmune diseases. Of 263 patients negative for routine
checkup, various aPLs were measured by commercial-based
laboratory, deﬁned 95th percentile and more as positive.
Then 132 patients were negative for any aPLs and 131
patients revealed positive for one or more aPL.
These 131 patients were treated with the anticoagulant
therapy, following which, 82 patients conceived. Of the 82
cases of conception, 74 maintained pregnancy successfully,
and 8 cases had a miscarriage before the 12th week of
pregnancy. Among these miscarriages, 7 cases exhibited
normal karyotypes of aborted villi and 1 case had chromo-
somal aberration. Therefore, with the exception of the case
involving chromosomal aberration, a total of 81 cases were
analyzed for reproductive outcomes with the anticoagulant
therapy. Pregnancy maintenance was deﬁned as the preg-
nancy continuing beyond the 24th week and resulting in the
delivery of a live-born neonate.
Figure 1 shows a summary of the patient groups and
numbers investigated the incidences of aPLs and the repro-
ductive outcomes with the anticoagulant therapy.
2.3. Measurement of Various aPLs and Deﬁnition of the Titer
as Positive. Peripheral blood was drawn from the patients
with negative routine checkup for RSA and various aPLs in
serumandplasmaweremeasured.Atthattime,patientswere
not pregnant. The test items concerning aPLs included LA,
aβ2GPI,aCL-IgGand-IgM,aPE-IgGand-IgM,andaPS-IgG
and-IgM.Acommercial-basedlaboratorytestcompany,SRL
Laboratory (Tokyo, Japan), measured all these aPLs.
LA was measured by the dilute Russell’s viper venom
time method [13] using a kit from Gradipore Ltd. (Aus-
tralia), and a control clotting time ratio (control individual
plasma clotting time/control pooled plasma clotting time)
corresponding to the 95th percentile of the value was deﬁned
as 1.12, and almost the 99th percentile was 1.3 in normal
Japanese population; therefore, the values were divided into
two groups, from 1.12 to 1.3 as weakly positive and higher
than 1.3 as strongly positive. A aβ2GPI was measured by
ELISA [14, 15] using a kit from Yamasa Co. (Japan), and
values from 1.9 (the 95th percentile) to 3.5 (almost the
99th percentile) U/mL were regarded as weakly positive andISRN Obstetrics and Gynecology 3
thosehigherthan3.5U/mLasstronglypositive.aCL-IgGwas
measured by ELISA using a MESACUP-IgG kit (MBL Co.,
Ltd., Japan), and values from 10U/mL corresponding to the
95th percentile to 20U/mL (almost the 99th percentile) were
regarded as weakly positive and those higher than 20U/mL
as strongly positive. aCL-IgM was measured by ELISA using
a kit from SRL Inc. (Japan), and values from 1.0U/mL
correspondingtothe95thpercentileto2.0U/mL(almostthe
99th percentile) were regarded as weakly positive and those
higher than 2.0U/mL as strongly positive. aPE-IgG, aPE-
IgM, aPS-IgG, and aPS-IgM were measured as previously
described [15, 16], and values from 0.300, 0.450, 1.0, and
1.0IU/mL,correspondingtothe95thpercentile,respectively,
calculated from 200 nonpregnant women, to 0.450, 0.750,
1.66, and 1.66U/mL (almost the 99th percentile), were
regarded as weakly positive [16, 17] and those higher than
the 99th percentile were regarded as strongly positive. So, in
this study, if the test items are 95th percentile and more, the
result is deﬁned as positive and anticoagulant therapy was
actively introduced.
2.4. Patient Treatment Protocols (Anticoagulant Therapy).
We performed anticoagulant therapy for all patients with
one or more aPLs positive RSA women. The anticoagulant
therapy consisted of two regimens, aspirin alone or aspirin
plus heparin. A daily dose of 100mg of aspirin was taken
orally from prior to conception until the 32nd week of
pregnancy, and subcutaneous self-injection of 5,000 units
of unfractionated heparin calcium was administered twice
a day, starting from the time when the presence of the
gestational sac was conﬁrmed in the uterus until the 37th
week of pregnancy.
Written informed consent concerning the application of
anticoagulanttherapieswasobtainedandthechoicebetween
these two regimens was left to patients.
2.5. Statistical Analysis. Diﬀerences between the two groups
wereanalyzedforsigniﬁcancewiththeχ2 orFisher exacttest.
3. Results
3.1. Incidence of Various aPLs, Measured Commercial-Based
Laboratory in Patients with RSA. The incidence of various
aPL proﬁles in two hundreds and sixty-three RSA patients
without anatomical, endocrine, or chromosomal aberration,
complication of SLE or other autoimmune diseases, was
shown in Table 1. Of these 263 patients, the mean age was
33.5 ± 4.7 years, and the mean number of spontaneous
abortions was 2.87 ± 1.03. Concerning individual aPL
without regarding the titer (weakly or strongly), the positive
(the 95th percentile and more) rate of aPS-IgM (73/263:
27.8%) was the highest, followed by aCL-IgM (71/263:
27.0%), LA (47/263: 17.9%), PE-IgG and -IgM (31/263:
11.8%), aCL-IgG (23/263: 8.7%), aPS-IgG (17/263: 6.5%),
and ﬁnally aβ2GPI (1/263: 0.4%). As for the incidence of
aPLs by isotype, in both aCL and aPS, IgM-isotype was more
frequent than IgG-isotype and in aPE, IgM-isotype and IgG-
isotype have the same frequency. As for the incidence of aPLs
bythetiter,intheweaklypositivegroup(fromthe95thtothe
99th percentile), the positive rates of aPL ranged from 0.4%
(1/263: aβ2GPI) to 19.4% (51/263: aPS-IgM), and in the
strongly positive group (over the 99th percentile), those of
aPL ranged from 0% (0/263: aβ2GPI) to 8.4% (22/263: aPS-
IgM). Comparing the incidence between these two groups, a
higher incidence was found in the weakly positive group in
all species of aPLs naturally.
3.2. Reproductive Outcomes of the Active Anticoagulant Ther-
apy in RSA Patients with aPL. The impact of various aPL
proﬁles on reproductive outcomes was shown in Tables 2
and 3. Of the 131 patients treated with the active anticoagu-
lant therapy by the method mentioned above, 82 cases led to
conception. After the exclusion of one case with chromoso-
mal aberration of aborted villi, 81 cases were ﬁnally analyzed
for reproductive outcomes. Total successful pregnancy rate
was 91.4% (74/81). For these 81 patients, the mean age
was 33.8 ± 4.0 years, and the mean number of spontaneous
abortions was 2.8 ± 0.9. When the 81 patients were divided
into 74 cases of successfully maintained pregnancy and 7
cases of abortion, the mean ages were 33.8 ± 4.1a n d3 4 .4 ±
4.0 years, and the mean numbers of spontaneous abortions
were 2.8 ± 1.0a n d2 .7 ± 0.8, respectively. No signiﬁcant
diﬀerences were found between these groups. Concerning
the variety of aPLs without titer, the rate of pregnancy
maintenance of 88.1% (37/42) in aPS-IgM positive cases was
the lowest among the various aPLs. However, no signiﬁcant
diﬀerence was found between all of each eight aPLs. For
instance, the P value of the diﬀerence between aCL-IgG (the
highest rate of pregnancy maintenance: 100%) and aPS-
IgM (the lowest rate of pregnancy maintenance: 88.1%)
was 0.176, and that of aCL-IgG versus aPS-IgG was 0.277.
As for the impact of the titer of aPLs, comparing the rate
of pregnancy maintenance in the weakly positive group
with that in the strongly positive group for each aPL, no
signiﬁcant diﬀerence was found among the six aPLs (IgG
and IgM of aCL, aPE, and aPS), and LA or aβ2GPI strongly
positive case was not here. For instance, the lowest P value
between weakly and strongly positive groups was 0.312
for aPE-IgG. As for the isotype (IgG or IgM group) and
the number (single positive or multiple positive group) of
positive aPLs, the impact of these on reproductive outcomes
was investigated. (Table 3) Eighty-one cases were divided
intotwogroups.TheIgMgroupcontained40caseswithonly
IgM-positive results and the IgG group contained 41 cases
with at least one IgG-positive result. The rate of pregnancy
maintenance in the IgM group was 90% (36/40), and that
in the IgG group was 92.7% (37/41), showing no signiﬁcant
diﬀerence between these two groups (P value: 0.667). As
for the number of positive aPLs, the rate of pregnancy
maintenanceinthe34caseswithasinglepositivegroup,with
onlyonepositive aPL,was91.2%(31/34) andthatin47cases
withmultiplepositivegroup,withtwoormorepositiveaPLs,
was 91.5% (43/47), also showing no signiﬁcant diﬀerence
between these two groups (P value: 0.961).4 ISRN Obstetrics and Gynecology
Table 1: Incidence of various aPL proﬁles in RSA patients without possible causes.
aPL type and titer aPL type aPL titer
Positive/tested (positive rate; %) Positive/tested (positive rate; %)
LA
weakly 47/263 (17.9%) 45/263 (17.1%)
strongly 2/263 (0.8%)
aβ2GPI
weakly 1/263 (0.4%) 1/263 (0.4%)
strongly 0/263 (0%)
aCL-IgG
weakly 23/263 (8.7%) 12/263 (4.6%)
strongly 11/263 (4.2%)
-IgM
weakly 71/263 (27.0%) 50/263 (19.0%)
strongly 21/263 (8.0%)
aPE-IgG
weakly 31/263 (11.8%) 22/263 (8.4%)
strongly 9/263 (3.4%)
-IgM
weakly 31/263 (11.8%) 23/263 (8.7%)
strongly 8/263 (3.0%)
aPS-IgG
weakly 17/263 (6.5%) 12/263 (4.6%)
strongly 5/263 (1.9%)
-IgM
weakly 73/263 (27.8%) 51/263 (19.4%)
strongly 22/263 (8.4%)
Positive titers of aPLs were deﬁned as follows:
LA: weakly; from 1.12 to 1.30, strongly; over 1.30.
aβ2GPI: weakly; from 1.9 to 3.5U/mL, strongly; over 3.5U/mL.
aCL-IgG: weakly; from 10 to 20U/mL, strongly; over 20U/mL.
aCL-IgM: weakly; from 1.0 to 2.0U/mL, strongly; over 2.0U/mL.
aPE-IgG: weakly; from 0.3 to 0.5 U/mL, strongly; over 0.5U/mL.
aPE-IgM: weakly; from 0.45 to 0.75 U/mL, strongly; over 0.75U/mL.
aPS-IgG: weakly; from 1.0 to 1.66U/mL, strongly; over 1.66U/mL.
aPS-IgM: weakly; from 1.0 to 1.66U/mL, strongly; over 1.66U/mL.
3 . 3 .T h eT h e r a p e u t i cO u t c o m eo ft h eT w oR e g i m e n sb yt h e
Isotype and Number of Positive aPLs. Finally, we intended to
identify a therapeutic principle for RSA patients with aPL.
Table 4 showed how the two regimens of anticoagulant
therapy, aspirin alone and aspirin plus heparin, impacted
on the reproductive outcomes, showing the results for the
isotype of positive aPLs or the number of positive aPLs.
There was a tendency for the rate of pregnancy maintenance
with aspirin alone to be lower than that with aspirin plus
heparin in the IgG group however, this did not constitute a
signiﬁcant diﬀerence (P value: 0.077). In IgM, single positive
and multiple positive group, there was no diﬀerence in
pregnancy maintenance rate between these two regimens.
4. Discussion
In the ﬁeld of obstetrics, APS has been mainly investigated
with regard to its relationship with pregnancy loss, and
therapy for aPL-positive recurrent pregnancy loss has been
studied. Although many points concerning the mechanism
of aPL-induced pregnancy loss remain unclear, according to
a systemic review of RCT by Empson et al. [6], the following
results have been shown. (1) A treatment combining low-
dose oral aspirin plus twice-a-day subcutaneous injections
of unfractionated heparin is beneﬁcial for patients with
aPL-positive recurrent pregnancy loss without other causes
of infertility, although its eﬃcacy for low-risk patient is
not clear. (2) Low-molecular-weight heparin is eﬀective,
although whether it exhibits an eﬀe c te q u i v a l e n tt ot h a to f
unfractionated heparin is not clear; the clariﬁcation of this
issue will require a large-scale RCT. (3) There is no evidence
for the eﬃcacy of other therapies such as immunoglobulin
and steroid treatments. As a consequence, anticoagulant
therapy mainly consisting of a combination of aspirin and
unfractionated heparin has become a standard therapy for
patients with aPL-positive recurrent pregnancy loss, and
currentlymanyfacilitiesperformthistreatmentasastandard
therapy. However, it should be kept in mind that the clinical
backgrounds of patients, the aPL species investigated, andISRN Obstetrics and Gynecology 5
Table 2: Reproductive outcomes of the anticoagulant therapy according to various aPL proﬁles in RSA patients.
Pregnancy
aPL species and titer Establisheda (n)
total 81
Maintaineda (n)
total 74
Aborteda (n)
total 7
Success rate (%) 91.4 P value
(weakly versus strongly)
Species Titer
LA
weakly 32 30 2 93.8 93.8 —
strongly 0 0 0 —
aβ2GPI
weakly 1 1 0 100 100 —
strongly 0 0 0 —
aCL-IgG
weakly 6 6 0 100∗, ∗∗ 100 —
strongly 8 8 0 100
-IgM
weakly 25 24 1 95.0 96.0 0.708
strongly 15 14 1 93.3
aPE-IgG
weakly 17 15 2 92.0 88.2 0.312
strongly 8 8 0 100
-IgM
weakly 12 11 1 94.1 91.7 0.506
strongly 5 5 0 100
aPS-IgG
weakly 6 5 1 90.0∗∗ 83.3 0.389
strongly 4 4 0 100
-IgM
weakly 28 24 4 88.1∗ 85.7 0.500
strongly 14 13 1 82.9
aSome patients had multiple positive aPLs.
P value for ∗was 0.176 and for ∗∗was 0.227.
Table 3: Reproductive outcomes of the anticoagulant therapy according to isotypes and the number of positive aPL in RSA patients.
The isotype or number of positive aPL
pregnancy (number)
Successful pregnancy rate (%) P value
Conceived Maintained Aborted
IgG groupa 41 38 3 92.7 av e r s u s
b = 0.667 IgM groupb 40 36 4 90.0
Single positive groupc 34 31 3 91.2 c versus
d = 0.961 Multiple positive groupd 47 43 4 91.5
aIgG group.
bIgM Group.
cSingle positive group.
dMultiple positive group.
the criteria of antibody titers are not necessarily consistent
among these reports. The laboratory criteria described in
the classiﬁcation criteria for APS are limited to aCL of IgG
or IgM isotype in a medium or higher titer, aβ2GPI of
IgG or IgM isotype, and LA. Sugi et al. reported a higher
frequency of aPE in patients with recurrent pregnancy loss
before the 10th week of gestation than in healthy women:
the frequencies of aPE-IgG, aPE-IgM, and aPE-IgA were
20.1%, 12.2%, and 1.4% in the patients, respectively, which
weresigniﬁcantlyhigherthanthoseinhealthywomen.These
ﬁndings suggested that aPE is strongly associated with early
pregnancy loss [9] and that aPE testing in addition to aPL
examinations of patients with infertility is advisable. Rote
et al. detected aPS at higher frequencies (IgG: 87%, IgM:
40%) than aCL (IgG: 68%, IgM: 36%) in patients with
idiopathicrecurrentpregnancyloss,suggestingastrongasso-
ciation of aPS with early pregnancy loss [8] and indicating
theimportanceofaPStesting.Pregnancylosswasconsidered
to occur at a high frequency in pregnant women with LA and
high titers of aCL-IgG [18, 19], and the risks of pregnancy
loss and obstetric complications in pregnant women with
low titers of aCL-IgG and aCL-IgM were found to be similar6 ISRN Obstetrics and Gynecology
Table 4: Reproductive outcomes in patients with RSA with aPL according to the kind of anticoagulant therapy.
kind of therapy The isotype or number of positive aPL
Pregnancy (n)
Successful pregnancy rate (%) P value
Established Maintained Aborted
Aspirin alone
IgG groupa 10 8 2 80.0 a versus
e = 0.077 IgM groupb 16 15 1 93.8
Single positive groupc 15 13 2 86.7 b versus
f = 0.519 Multiple positive groupd 11 10 1 90.9
Aspirin + heparin
IgG groupe 31 30 1 96.8 cv e r s u s
g = 0.410 IgM groupf 24 21 3 87.5
Single positive groupg 19 18 1 94.7 d versus
h = 0.937 Multiple positive grouph 36 33 3 91.7
aIgG group with aspirin.
bIgM Group with aspirin.
cSingle positive group with aspirin.
dMultiple positive group with aspirin.
eIgG group with aspirin plus heparin.
fIgM Group with aspirin plus heparin.
gSingle positive group with aspirin plus heparin.
hMultiple positive group with combination therapy of aspirin plus heparin.
to those in pregnant women negative for these antibodies
[20], while low titers of aPL were not found to be clinically
signiﬁcant [21]. The clinical signiﬁcance of the aPL isotypes
other than IgG, such as IgM and IgA, including aCL, is
still unclear. Matzner et al. investigated 6 species of aPL
including aCL in 352 patients with recurrent pregnancy loss
and detected aPL in about 60% of the patients, but the
antibodies were IgM in 75% of patients [22], suggesting that
the IgM antibodies were also pathogenic. However, the rate
of pregnancy loss due to aCL-IgM alone was found to be
similar to that in aPL-negative women [20]. Moreover, Aoki
et al. reported that fetal loss recurred in 27 cases (82%)
out of 33 IgG aPL-positive patients when testing aPE, aPS,
antiphosphatidylinositol antibody (aPI), and aCL without
treatment and in 2 cases (40%) out of 5 IgG aPL-negative
but IgM aPL-positive patients, and fetal loss recurred in all
21 patients that were aPL-positive with two or more IgG
types. They concluded that the IgG isotype of aPLs was more
pathogenic than that of IgM and two or more IgG-positive
cases were more at risk than one-IgG-positive cases [23].
In this study, concerning individual aPL without regard-
ing the titer, the positive rates of aCL-IgM and aPS-IgM
exceeded 25%, while that of aβ2GPI was very low, only
0.4%. Those of other aPLs were found to be between
6.5% (aPS-IgG) and 17.9% (LA). This high positive rate,
regarded the 95th percentile and more as positive, for aCL-
I g Ma n da P S - I g Mi nR S Aw o m e nw a sﬁ v et i m e sa sh i g ha s
normal Japanese population, and aCL and aPS may have had
stronger association with RSA than aβ2GPI, consistent with
previous reports [8, 22]. With regard to the isotype of aPL,
the positive rates of aCL-IgM and aPS-IgM were very high,
and those of CL-IgG (8.7%) and aPS-IgG (6.5%) were lower
than aCL-IgM and aPS-IgM, suggesting that the IgM isotype
of aPLs may also have been pathogenic for early RSA, and
these antibodies are worth testing in RSA women. Moreover,
strongly positive case (over the 99th percentile) of LA and
aβ2GPI were more scarce than normal Japanese population
(0.8% and 0%, resp.), suggesting relatively high association
with early RSA and IgG or IgM of aCL, aPE, and aPS.
With regard to the reproductive outcome of the anti-
coagulant therapy in patients that had undergone RSA
and had any aPLs, the rate of pregnancy maintenance of
88.1% (37/42) in aPS-IgM-positive cases was the lowest,
but there was no signiﬁcant diﬀerence among the other
eight aPLs in terms of the rate of pregnancy maintenance.
There was no LA and aβ2GPI for strongly positive conceived
patient in this study, with regard to the titer of each aPL,
upon comparing the pregnancy maintenance rate of weakly
positive with strongly positive groups for each aPL, no
signiﬁcant diﬀerences were found for all 8 aPLs (Table 2). As
mentioned before [18, 19], pregnant women with LA and/or
high titer of aCL-IgG were thought to be high risk of RSA,
but in fact, the rate of pregnancy maintenance of LA weakly
positive RSA patients is 93.8% and that of aCL-IgG strongly
positive RSA patients is 100%. No signiﬁcant diﬀerence due
to APL species or titer in the pregnancy maintenance rate
was identiﬁed in this study. Active anticoagulant therapy
enabled the normal maintenance of pregnancy regardless of
thepositiveantibodyspeciesandtiter,andnormalpregnancy
was maintained in 91.4% of cases on average.
Next, we investigated the impacts of the isotype of aPLs,
namely, IgG group or IgM group, and the number of positive
aPLs, namely, single or multiple, on reproductive outcomes.
All patients with positive LA or aβ2GPI had other aPLs
measured in this study. The rate of pregnancy maintenance
in the IgM group was 90.0% and that in the IgG group
was 92.7%, showing no signiﬁcant diﬀerence. With regard
to the number of positive aPLs, the rate of pregnancy
maintenance in 34 cases with single aPL was 91.2% and that
in 47 cases with multiple aPLs was 91.5%, also showing no
signiﬁcant diﬀerence (Table 3), so we concluded that active
anticoagulant therapy for aPL positive RSA patients will
result in good pregnancy outcome regardless of the isotype
and the number of positive aPLs.ISRN Obstetrics and Gynecology 7
Finally,weintendedtoidentifyatherapeuticprinciplefor
RSA patients with aPL. There was a tendency for the rate of
pregnancy maintenance with aspirin alone to be lower than
that with aspirin plus heparin in the IgG group; however, no
signiﬁcant diﬀerence was found (P value: 0.077), showing
a beneﬁt of combination therapy for IgG group and higher
pathogenicity in the IgG than IgM group. Moreover, the rate
of pregnancy maintenance did not diﬀer between patients
treated with aspirin alone and those with a combination of
aspirin plus heparin in the IgM group, so aspirin therapy
alone is suﬃcient for the IgM group because heparin therapy
was very stressful for patients. As mentioned before [20, 22,
23], the clinical signiﬁcance of the aPLs isotype of IgM was
not clear, but IgM isotype may have had some pathogenicity
for early recurrent abortion and may have been weaker than
that of IgG.
A limitation of this study may be the consideration of
the pregnancy maintenance rate without control patients
(without anticoagulant therapy), including patient overlap
for aPL positivities and not RCT but retrospective cohort
study. This pregnancy maintenance rate is as high as normal
Japanesepopulationafteranintrauterinepregnancyhasbeen
seen by ultrasound, and this study may include normal
population because we have resulted from the 95th to the
99th percentile as weakly positive. The interpretation of the
result needs to be careful and the accumulation of additional
cases and more detailed investigations may be necessary.
5. Conclusion
Because IgG or IgM of aCL, aPE, and aPS were more
frequent than LAC or aβ2GPI in RSA patients, we have
to test these aPLs for RSA patients checkup. The patients
suﬀering from RSA with some aPLs and do not meet criteria
for APS resulted in normal pregnancy outcome by active
anticoagulant therapy regardless of the positive antibody
species, titer, and the number. In terms of the pathogenicity
of aPLs, IgG isotype may be stronger than IgM isotype, so we
recommend combination therapy with aspirin and heparin
for IgG-positive RSA patients.
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